PuSH - Publication Server of Helmholtz Zentrum München

14 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Salminen, A.V. et al.: Reply to: A note on rotigotine for restless legs syndrome after renal transplantation. Mov. Disord. 34, 152-153 (2019)
2.
Salminen, A.V. et al.: Reply to: Safety of dopamine agonists for treating restless legs syndrome. Mov. Disord. 34, 150-151 (2019)
3.
Winkelmann, J. et al.: Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§. Mov. Disord. 33, 1077-1091 (2018)
4.
Allen, R.P.* et al.: Animal models of RLS phenotypes. Sleep Med. 31, 23-28 (2017)
5.
Garcia Borreguero, D.* ; Winkelmann, J. & Allen, R.P.*: Introduction: Towards a better understanding of the science of RLS/WED. Sleep Med. 31, 1-2 (2017)
6.
Schormair, B. et al.: Identification of novel risk loci for restless legs syndrome: A meta-analysis of genome-wide association studies in individuals of European ancestry: A meta-analysis. Lancet Neurol. 16, 898–907 (2017)
7.
Connor, J.R.* ; Patton, S.M.* ; Oexle, K. & Allen, R.P.*: Iron and restless legs syndrome: Treatment, genetics and pathophysiology. Sleep Med., accepted (2016)
8.
García-Borreguero, D.* et al.: Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: A combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 21, 1-11 (2016)
9.
Trenkwalder, C.* ; Allen, R.P.* ; Högl, B.* ; Paulus, W.* & Winkelmann, J.: Restless legs syndrome associated with major diseases: A systematic review and new concept. Neurology 86, 1336-1343 (2016)
10.
Wain, L.V.* et al.: Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): A genetic association study in UK Biobank. Lancet Resp. Med. 3, 769-781 (2015)
11.
Trenkwalder, C.* et al.: Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 12, 1141-1150 (2013)
12.
Winkelmann, J. et al.: Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet. 7:e1002171 (2011)
13.
García-Borreguero, D.* et al.: Augmentation as a treatment complication of restless legs syndrome: Concept and management. Mov. Disord. 22, (Suppl.18), 476-484 (2007)
14.
García-Borreguero, D.* et al.: Diagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 8, 520-530 (2007)